Open in interactive viewer → charts, metric popovers & call review

Ypsomed's First Guidance Raise in 14 Years Is Not a GLP-1 Story

Autoinjector mix, a capacity build and a newly explicit China M&A option are doing the work — but the margin peak may be now.
YPSN.SW · Earnings Call · 2026-11-11

The raise is real — and narrower than the headline

Ypsomed delivered CHF 318 million of H1 sales, with Delivery Systems up 17.5% and commercial sales rising more than 20% to CHF 243 million. EBIT came in at CHF 102 million, a 35.7% margin, and management raised full-year sales growth guidance to 13%–16% from 12%–15% and EBIT to CHF 220–240 million from CHF 210–230 million. The CEO framed it as a genuine first: “the first time in my 14 years as a CEO here at Ypsomed, we are raising the bar. We are raising the guidance for the full year.” — Simon Michel, CEO · 2026-11-11 The important nuance is where the growth is coming from. This was not a broad market wave: the global keyword tape is dominated by AI data centers, memory pricing, tariffs and Fed policy, not by self-injection devices. Ypsomed's story is company-specific execution. Management signed 30 new deals in six months — over two-thirds of the prior full year — and added 10 customers to reach 130. But only a few of those deals were GLP-1. The real growth driver was the auto-injector platform, especially the 1 ml and 2.25 ml YpsoMate lines. The pen business grew less than the group average, and management was explicit that large volume biologics — autoimmune, neurology, some oncology — are pulling the mix toward higher-value devices. That matters because the market's default Ypsomed narrative has been GLP-1. The current call pushes back on that: incretins are above 10% of sales but, in management's words, way below one-third. The incretin space is optionality, not the base case. The base case is a broad autoimmune and large-volume autoinjector franchise, and that franchise carries pricing power. As the CEO put it:

We have asked all our clients, how do you perceive us? And in fact, the majority perceives us as not the cheapest one. So we are actually perceived as the most expensive one in the industry. But 99% — I think it was 1 out of 85 clients said they are too expensive.

Simon Michel, CEO · 2026-11-11

The margin peak is the real debate

A 35.7% H1 EBIT margin is exceptional, but the guidance implies a lower second half. Management cited ramp-up costs, product mix and biosimilar pricing in China. The answer on the margin trajectory was deliberately vague: “So frankly speaking, all we have guided is above 30%. It doesn't mean we need to reach 30%. It may also mean we are way above 30%.” — Simon Michel, CEO · 2026-11-11 That is the tension in the stock. The company is raising the near-term number while telling investors the margin glide path slopes down before it slopes back up. The YpsoFit cost program is central to that slope. On the prior call, the CFO sized it as a low double-digit million P&L benefit spread over three to five years. On this call, it has become something bigger and later: “The program has actually gotten much bigger than we originally expected... You will not see a benefit in '27. It will soften the EBIT effect in '28/'29.” — Simon Michel, CEO · 2026-11-11 The mechanics are concrete: move clients from medical grade to food-grade plastics, dual-source resin, and share 3–4 percentage points of EBIT benefit with customers. That is a real structural cost lever, but it is a 2028–2029 story, not a 2027 rescue. At the same time, the capex cycle is peaking. Fixed asset investment is expected near CHF 300 million this year, with plastic molding lines being installed across Germany, China and the U.S. Free cash flow should turn positive in FY27/28, net debt/EBITDA is around 1.0 and ROCE is still around 20%. So the margin fade is not a balance-sheet problem; it is the cost of building capacity ahead of contracts.

China: from 'close look' to an explicit M&A option

The most company-unique keyword in the current quarter is close look, tied to China. Management laid out three paths into the Chinese value segment: a new low-cost NeoPen platform, a contract-manufacturing partnership, and — new this quarter — acquiring a local Chinese manufacturer. They said they had analyzed roughly 30 Chinese pen manufacturers and found four or five serious enough to consider. “We're actually also looking at acquiring a local Chinese manufacturer. We have done the analysis. We have looked at a very broad space of Chinese pen manufacturers, roughly 30.” — Simon Michel, CEO · 2026-11-11 That is an escalation from the prior call, when China competition was framed more defensively. In May, the IR lead said: “there's also a possibility eventually in the future to collaborate with some of them for the local or the regional market.” — Sam Ghezelbash, IR or Investor Relations Officer · 2026-05-20 Now collaboration has become a strategic menu that includes acquisition. The logic is clear: Ypsomed will not cut prices on its existing YpsoMate or UnoPen platforms to win domestic volume, but it does want to participate in the value segment without damaging the premium franchise. That is a sensible ring-fence, though it adds integration and execution risk to an already heavy capex program.

What changed — and what did not

The prior call described the growth path as “pretty linear... we are a bit slower in '26, '27, and we will catch up a bit in '27, '28.” — Simon Michel, CEO · 2026-05-20 This call says the kink is gone: “We definitely don't see any more this kink, this slowing down in '27/'28... it will be much smoother than we expected half a year ago.” — Simon Michel, CEO · 2026-11-11 That is a meaningful change in tone and in near-term visibility. The midterm ambition — CHF 0.9–1.1 billion of sales and CHF 280–340 million of EBIT by FY29/30 — was confirmed, not raised. So the company is ahead of its own plan, but it is not yet rewriting the destination. The thing management quietly de-emphasized is GLP-1. It is still there, still growing, still strategically relevant, but it is no longer the lead character. The lead character is the autoinjector franchise, the capacity build and the China option. That is a better story than a pure GLP-1 proxy — more diversified, more pricing-power-led, less dependent on one therapeutic fashion. But it also means the next 18–24 months are about executing a margin glide path in the mid-30s while ramping plants on three continents. The first guidance raise in 14 years is a confidence signal. The margin trajectory is the proof point investors will watch.